Switch theme
Sign up to access all valuation multiples
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
2007
192
LTM Revenue $96.2M
LTM EBITDA -$213M
-$156M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Kura Oncology has a last 12-month revenue (LTM) of $96.2M and a last 12-month EBITDA of -$213M.
In the most recent fiscal year, Kura Oncology achieved revenue of $53.9M and an EBITDA of -$169M.
Kura Oncology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Kura Oncology valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $96.2M | XXX | $53.9M | XXX | XXX | XXX |
| Gross Profit | $95.8M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$213M | XXX | -$169M | XXX | XXX | XXX |
| EBITDA Margin | -222% | XXX | -315% | XXX | XXX | XXX |
| EBIT | -$174M | XXX | -$193M | XXX | XXX | XXX |
| EBIT Margin | -181% | XXX | -359% | XXX | XXX | XXX |
| Net Profit | -$159M | XXX | -$174M | XXX | XXX | XXX |
| Net Margin | -165% | XXX | -323% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Kura Oncology's stock price is $6.
Kura Oncology has current market cap of $483M, and EV of -$156M.
See Kura Oncology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$156M | $483M | XXX | XXX | XXX | XXX | $-1.92 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Kura Oncology has market cap of $483M and EV of -$156M.
Kura Oncology's trades at -2.9x EV/Revenue multiple, and 0.9x EV/EBITDA.
Equity research analysts estimate Kura Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kura Oncology has a P/E ratio of -3.0x.
See valuation multiples for Kura Oncology and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $483M | XXX | $483M | XXX | XXX | XXX |
| EV (current) | -$156M | XXX | -$156M | XXX | XXX | XXX |
| EV/Revenue | -1.6x | XXX | -2.9x | XXX | XXX | XXX |
| EV/EBITDA | 0.7x | XXX | 0.9x | XXX | XXX | XXX |
| EV/EBIT | 0.9x | XXX | 0.8x | XXX | XXX | XXX |
| EV/Gross Profit | -1.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.0x | XXX | -2.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKura Oncology's last 12 month revenue growth is 79%
Kura Oncology's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $1.3M for the same period.
Kura Oncology's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kura Oncology's rule of X is -24% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Kura Oncology and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 79% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -222% | XXX | -315% | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | 25% | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | -236% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -24% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 315% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 459% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kura Oncology acquired XXX companies to date.
Last acquisition by Kura Oncology was XXXXXXXX, XXXXX XXXXX XXXXXX . Kura Oncology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Kura Oncology founded? | Kura Oncology was founded in 2007. |
| Where is Kura Oncology headquartered? | Kura Oncology is headquartered in United States of America. |
| How many employees does Kura Oncology have? | As of today, Kura Oncology has 192 employees. |
| Who is the CEO of Kura Oncology? | Kura Oncology's CEO is Dr. Troy E. Wilson, PhD, J.D.. |
| Is Kura Oncology publicy listed? | Yes, Kura Oncology is a public company listed on NAS. |
| What is the stock symbol of Kura Oncology? | Kura Oncology trades under KURA ticker. |
| When did Kura Oncology go public? | Kura Oncology went public in 2015. |
| Who are competitors of Kura Oncology? | Similar companies to Kura Oncology include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Kura Oncology? | Kura Oncology's current market cap is $483M |
| What is the current revenue of Kura Oncology? | Kura Oncology's last 12 months revenue is $96.2M. |
| What is the current revenue growth of Kura Oncology? | Kura Oncology revenue growth (NTM/LTM) is 79%. |
| What is the current EV/Revenue multiple of Kura Oncology? | Current revenue multiple of Kura Oncology is -1.6x. |
| Is Kura Oncology profitable? | Yes, Kura Oncology is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Kura Oncology? | Kura Oncology's last 12 months EBITDA is -$213M. |
| What is Kura Oncology's EBITDA margin? | Kura Oncology's last 12 months EBITDA margin is -222%. |
| What is the current EV/EBITDA multiple of Kura Oncology? | Current EBITDA multiple of Kura Oncology is 0.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
